Margaret Dolan | Regional Pharmacy Procurement Specialist
N.H.S.

Margaret Dolan, Regional Pharmacy Procurement Specialist, N.H.S.

Maggie achieved her BSc pharmacy at Heriot Watt University, Edinburgh, and a diploma in clinical pharmacy from Strathclyde University in 1991. She has many years of experience as a hospital clinical pharmacist primarily in Scotland. She was Chief Pharmacist in Edinburgh in both the adult (West Lothian NHS Trust) and paediatric (Edinburgh sick Children’s Hospital ) setting over the period 1993-2005.Throughout her career she has developed a keen interest in the safe, effective and cost effective procurement of medicines to the benefit of both individual patients and the NHS economy. As pharmacy advisor to National Procurement Scotland she was seconded to
Scottish Government to work on Pandemic Flu Preparedness. Her current role is as Regional Medicine Procurement Specialist for the South East Coast. She chairs the NHS Biosimilars Group, the Purchasing and Distribution Interest Group and is a member of the Carter Review Group as co-chair of the contracting team.

Appearances:



Biosimilars Day 1 - Tuesday 31st October 2017 @ 09:50

International stakeholders panel discussion: What does it take to get biosimilars moving in a country?

  • Consisting of industry panellists, physicians, pharmacists, patient advocacy groups, payers, regulators and health authorities, the 360° Perspective Panel allows the whole industry to come together to discuss and debate the sector’s most pertinent topics of the day.
     
  • With no guarantee that physicians will prescribe biosimilars interchangeably with reference products, what more does the industry need to do to encourage biosimilar uptake within healthcare?
  • What can we learn from gainsharing practices? Carrot & stick models, which works better?
  • How influential are payers in the speed in which biosimilars are taken up in healthcare systems?
  • How does the industry envisage overcoming the challenge that patient communities are generally unaware of this new, yet important, category of medicines?

back to speakers